Retro Biosciences Adjusts Dosing in Alzheimer’s Trial for RTR-242
Edited by Vita Solenne
Research & Biotech · Updated September 25, 2026
Retro Biosciences, a startup backed by Sam Altman, is expanding its clinical trial for the Alzheimer’s treatment pill RTR-242 after initial doses showed no adverse effects. The company is now addressing the challenge of moving forward with a trial where the early results were uneventful, indicating a need for adjustments in dosing to ensure efficacy. This development highlights the complexities of drug trials, especially in the field of neurodegenerative diseases.
Share this story
Why it matters
- ✓Advancements in Alzheimer’s treatments could lead to improved quality of life for aging populations.
- ✓Understanding the dosing adjustments can inform health optimizers about the importance of clinical trial phases in drug development.
- ✓The focus on safety and efficacy in trials reflects a commitment to developing reliable longevity solutions.
Retro Biosciences Adjusts Dosing in Alzheimer’s Trial for RTR-242
Introduction
Retro Biosciences, a biotechnology startup supported by prominent investor Sam Altman, is making headlines with its recent decision to expand the clinical trial for its Alzheimer’s treatment pill, RTR-242. This adjustment comes after the initial doses of the drug showed no adverse effects, a situation that, while generally favorable, poses unique challenges for the trial's progression.
Background on RTR-242
RTR-242 is designed to target Alzheimer’s disease, a condition that affects millions worldwide and poses significant challenges for patients and caregivers alike. The drug aims to provide a new avenue for treatment in a field where options are limited and often ineffective. Retro Biosciences’ approach reflects a growing interest in developing innovative therapies for neurodegenerative diseases, particularly as the global population ages.
The Clinical Trial Expansion
The decision to widen the trial follows the initial phase, which yielded a
Sources
- Retro Biosciences tweaks its Alzheimer’s pill dosing — Longevity Technology
Newsletter
Your weekly longevity signal. No spam.
Comments
Log in with
Loading comments…
More in Biotech
Fractyl Revita Shows Promise in Reducing Weight Regain After GLP-1 Therapy
Fractyl Health has announced positive results from the REMAIN-1 pivotal study, which evaluated the…
Just now
Exploring the Connection Between Big Pharma and Gray-Market Peptides
A recent analysis reveals significant ties between the pharmaceutical industry and gray-market…
2d ago
Kailera Completes Enrollment for Obesity Trials, Results Expected in 2028
Kailera has completed enrollment for its three Phase 3 trials of ribupatide, a weekly injection…
2d ago
Longeveron’s Stem Cell Therapy Shows Promise for Reducing Brain Inflammation in Alzheimer’s Patients
Longeveron has released new preclinical data suggesting that its stem cell therapy may lead to…
2d ago